GnRH Agonist and HCG (dual Trigger) Versus HCG Trigger for Follicular Maturation: a Systematic Review and Meta-analysis of Randomized Trials

Overview

Journal Reprod Biol Endocrinol

Publisher Biomed Central

Specialties Endocrinology
Reproductive Medicine

Date 2021 Jun 1

PMID 34059045

Citations 10

Authors

Kai-Lun Hu

Siwen Wang

Xiaohang Ye

Dan Zhang

Sarah Hunt

Affiliations

Soon will be listed here.

Abstract

Background: Traditionally, final follicular maturation is triggered by a single bolus of human chorionic gonadotropin (hCG). This acts as a surrogate to the naturally occurring luteinizing hormone (LH) surge to induce luteinization of the granulosa cells, resumption of meiosis and final oocyte maturation. More recently, a bolus of gonadotropin-releasing hormone (GnRH) agonist in combination with hCG (dual trigger) has been suggested as an alternative regimen to achieve final follicular maturation.

Methods: This study was a systematic review and meta-analysis of randomized trials evaluating the effect of dual trigger versus hCG trigger for follicular maturation on pregnancy outcomes in women undergoing in vitro fertilization (IVF). The primary outcome was the live birth rate (LBR) per started cycle.

Results: A total of 1048 participants were included in the analysis, with 519 in the dual trigger group and 529 in the hCG trigger group. Dual trigger treatment was associated with a significantly higher LBR per started cycle compared with the hCG trigger treatment (risk ratio (RR) = 1.37 [1.07, 1.76], I = 0%, moderate evidence). There was a trend towards an increase in both ongoing pregnancy rate (RR = 1.34 [0.96, 1.89], I = 0%, low evidence) and implantation rate (RR = 1.31 [0.90, 1.91], I = 76%, low evidence) with dual trigger treatment compared with hCG trigger treatment. Dual trigger treatment was associated with a significant increase in clinical pregnancy rate (RR = 1.29 [1.10, 1.52], I = 13%, low evidence), number of oocytes collected (mean difference (MD) = 1.52 [0.59, 2.46), I = 53%, low evidence), number of mature oocytes collected (MD = 1.01 [0.43, 1.58], I = 18%, low evidence), number of fertilized oocytes (MD = 0.73 [0.16, 1.30], I = 7%, low evidence) and significantly more usable embryos (MD = 0.90 [0.42, 1.38], I = 0%, low evidence).

Conclusion: Dual trigger treatment with GnRH agonist and HCG is associated with an increased live birth rate compared with conventional hCG trigger.

Trial Registration: CRD42020204452 .

Citing Articles

A cost analysis of hCG trigger alone versus dual trigger for achieving live birth following in vitro fertilization.

Chung E, Khorshid A, Bavan B, Lathi R Reprod Fertil. 2025; 6(1).

PMID: 39832451 PMC: 11850038. DOI: 10.1530/RAF-24-0095.

Dual trigger versus human chorionic gonadotropin trigger for blastocyst quality and cumulative live birth.

He Z, Liu Y, Huang N, Liu X, Zeng L, Lian Y J Assist Reprod Genet. 2024; 41(12):3445-3453.

PMID: 39549203 PMC: 11707115. DOI: 10.1007/s10815-024-03293-5.

In Vitro Fertilization Outcomes With a Dual Trigger in Normoresponders in Antagonist Cycles.

Cevher Akdulum M, Arik S, Demirdag E, Erdem M, Erdem A Cureus. 2023; 15(9):e45623.

PMID: 37868584 PMC: 10588958. DOI: 10.7759/cureus.45623.

Dual trigger and the impact on oocyte quality and embryo development: a Brazilian cohort.

Kozlowski I, Rosa V, Francisquini C, Schuffner A JBRA Assist Reprod. 2023; .

PMID: 37768818 PMC: 10718541. DOI: 10.5935/1518-0557.20230048.

Beyond the Umbrella: A Systematic Review of the Interventions for the Prevention of and Reduction in the Incidence and Severity of Ovarian Hyperstimulation Syndrome in Patients Who Undergo In Vitro Fertilization Treatments.

Palomba S, Costanzi F, Nelson S, Besharat A, Caserta D, Humaidan P Int J Mol Sci. 2023; 24(18).

PMID: 37762488 PMC: 10531768. DOI: 10.3390/ijms241814185.

References

Humaidan P, Papanikolaou E, Tarlatzis B . GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod. 2009; 24(10):2389-94. DOI: 10.1093/humrep/dep246. View

Schachter M, Friedler S, Ron-El R, Zimmerman A, Strassburger D, Bern O . Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril. 2007; 90(4):1087-93. DOI: 10.1016/j.fertnstert.2007.07.1316. View

Ludwig M, Doody K, Doody K . Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril. 2003; 79(5):1051-9. DOI: 10.1016/s0015-0282(03)00173-0. View

Ali S, Elsenosy E, Sayed G, Farghaly T, Youssef A, Badran E . Dual trigger using recombinant HCG and gonadotropin-releasing hormone agonist improve oocyte maturity and embryo grading for normal responders in GnRH antagonist cycles: Randomized controlled trial. J Gynecol Obstet Hum Reprod. 2020; 49(5):101728. DOI: 10.1016/j.jogoh.2020.101728. View

Haas J, Zilberberg E, Nahum R, Mor Sason A, Hourvitz A, Gat I . Does double trigger (GnRH-agonist + hCG) improve outcome in poor responders undergoing IVF-ET cycle? A pilot study. Gynecol Endocrinol. 2019; 35(7):628-630. DOI: 10.1080/09513590.2019.1576621. View

Chen C, Tzeng C, Wang P, Liu W, Chang H, Chen H . Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis. Arch Gynecol Obstet. 2018; 298(1):17-26. DOI: 10.1007/s00404-018-4751-3. View

Gonen Y, Balakier H, Powell W, Casper R . Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990; 71(4):918-22. DOI: 10.1210/jcem-71-4-918. View

Eftekhar M, Farid Mojtahedi M, Miraj S, Omid M . Final follicular maturation by administration of GnRH agonist plus HCG versus HCG in normal responders in ART cycles: An RCT. Int J Reprod Biomed. 2017; 15(7):429-434. PMC: 5601934. View

Raga F, Casan E, Kruessel J, Wen Y, Bonilla-Musoles F, Polan M . The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology. 1999; 140(8):3705-12. DOI: 10.1210/endo.140.8.6899. View

10.

Shapiro B, Daneshmand S, Garner F, Aguirre M, Thomas S . Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril. 2007; 90(1):231-3. DOI: 10.1016/j.fertnstert.2007.06.030. View

11.

Kim C, Ahn J, You R, Kim S, Chae H, Kang B . Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization. J Reprod Med. 2014; 59(1-2):63-8. View

12.

Lin M, Wu F, Hwu Y, Lee R, Li R, Li S . Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve. Reprod Biol Endocrinol. 2019; 17(1):7. PMC: 6320621. DOI: 10.1186/s12958-018-0451-x. View

13.

Chern C, Li J, Tsui K, Wang P, Wen Z, Lin L . Dual-trigger improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve: A retrospective cohort study. PLoS One. 2020; 15(7):e0235707. PMC: 7337315. DOI: 10.1371/journal.pone.0235707. View

14.

Fernando S, Wallace E, Vollenhoven B, Lolatgis N, Hope N, Wong M . Melatonin in Assisted Reproductive Technology: A Pilot Double-Blind Randomized Placebo-Controlled Clinical Trial. Front Endocrinol (Lausanne). 2018; 9:545. PMC: 6157331. DOI: 10.3389/fendo.2018.00545. View

15.

Li S, Zhou D, Yin T, Xu W, Xie Q, Cheng D . Dual trigger of triptorelin and HCG optimizes clinical outcome for high ovarian responder in GnRH-antagonist protocols. Oncotarget. 2018; 9(4):5337-5343. PMC: 5797053. DOI: 10.18632/oncotarget.23916. View

16.

Zegers-Hochschild F, Adamson G, Dyer S, Racowsky C, de Mouzon J, Sokol R . The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril. 2017; 108(3):393-406. DOI: 10.1016/j.fertnstert.2017.06.005. View

17.

Lin M, Wu F, Lee R, Li S, Lin S, Hwu Y . Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril. 2013; 100(5):1296-302. DOI: 10.1016/j.fertnstert.2013.07.1976. View

18.

Orvieto R . Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?. J Ovarian Res. 2015; 8:60. PMC: 4546254. DOI: 10.1186/s13048-015-0187-6. View

19.

Thoma M, McLain A, Louis J, King R, Trumble A, Sundaram R . Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. Fertil Steril. 2013; 99(5):1324-1331.e1. PMC: 3615032. DOI: 10.1016/j.fertnstert.2012.11.037. View

20.

Humaidan P, Bredkjaer H, Bungum L, Bungum M, Grondahl M, Westergaard L . GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005; 20(5):1213-20. DOI: 10.1093/humrep/deh765. View